Salarius Pharmaceuticals, Inc.

0.71 USD
+0.07 (+10.94%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Salarius Pharmaceuticals, Inc. stock is down -6.58% since 30 days ago. The next earnings date is Mar 25, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 10% of the previous 13 December’s closed higher than November.

About Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company is headquartered in Houston, Texas.